Breaking News Instant updates and real-time market news.

INSM

Insmed

, AZN

AstraZeneca

$32.57

-0.43 (-1.30%)

07:00
10/05/16
10/05
07:00
10/05/16
07:00

Insmed signs licensing agreement with AstraZeneca for DDP1 inhibitor

Insmed (INSM) announced a licensing agreement with AstraZeneca (AZN) for global exclusive rights to AZD7986, a novel oral inhibitor of dipeptidyl peptidase I, or DPP1. DPP1 is an enzyme that catalyzes the activation of neutrophil serine proteases, which play a key role in pulmonary diseases such as non-cystic fibrosis bronchiectasis. Insmed has renamed the compound INS1007 and will pursue an initial indication of non-CF bronchiectasis, a rare, progressive, neutrophil-driven pulmonary disorder in which the bronchi become permanently dilated due to chronic inflammation and infection. The estimated global prevalence of non-CF bronchiectasis exceeds 2 million, of which at least 110,000 cases are in the U.S. There is currently no cure for non-CF bronchiectasis. Insmed is completing its plans for a phase 2 study in non-CF bronchiectasis. The study is expected to begin in 2017. Insmed will pay AstraZeneca an upfront payment of $30M. AstraZeneca will be eligible to receive future payments totaling $120M in future clinical, regulatory, and sales-related milestones. AstraZeneca would also be entitled to receive tiered royalties ranging from a high single-digit to mid-teen. In addition, the agreement provides AstraZeneca with the option to negotiate a future agreement with Insmed for commercialization of AZD7986/INS1007 in chronic obstructive pulmonary disease or asthma.

INSM

Insmed

AZN

AstraZeneca

$32.57

-0.43 (-1.30%)

  • 07

    Oct

  • 13

    Oct

  • 16

    Nov

INSM Insmed

12/18/15
SBSH
12/18/15
DOWNGRADE
Target $7
SBSH
Neutral
Synergy Pharmaceuticals downgraded to Neutral from Buy at Citi
Citi analyst Liav Abraham downgraded Synergy Pharmaceuticals (SGYP) to Neutral saying the commercial potential of plecanatide will be "significantly lower" than that of Linzess. He also views the probability of a takeout of the company as less likely. The analyst cut his price target for the shares to $7 from $12. Abraham calls Synergy and Insmed (INSM) his least favored small-cap Specialty Pharma names for 2016.
03/15/16
STFL
03/15/16
INITIATION
Target $23
STFL
Buy
Insmed initiated with a Buy at Stifel
Target $23.
06/09/16
PIPR
06/09/16
NO CHANGE
Target $24
PIPR
Overweight
Insmed withdrawal in Europe does little to change outlook, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says Insmed's decision to withdraw its Marketing Authorization Application from the European Medicines Agency for Arikayce for the treatment of nontuberculous mycobacteria lung disease does little to change the company's outlook. Like the FDA, the European regulators want to see the results of the full Phase 3 Convert study, which will report in 2017, Schimmer tells investors in a research note. Success in the Phase 3 trial likely would have been needed to stay on the market anyways, the analyst contends. He keeps an Overweight rating on Insmed with a $24 price target.
06/09/16
LEER
06/09/16
NO CHANGE
Target $21
LEER
Outperform
Insmed withdrawal in Europe a minor setback, says Leerink
Leerink analyst Joseph Schwartz says Insmed decided to withdraw its Marketing Authorization Application from the European Medicines Agency for its Arikayce in treating patients with nontuberculous mycobacterium infections. The analyst sees this setback as minor as Phase 3 CONVERT study continues to enroll patients allowing the company to return with "better, more convincing" clinical data at a later date. Schwartz reiterates an Outperform rating on the stock but lowered his price target on the shares to $21 from $23.
AZN AstraZeneca
$32.57

-0.43 (-1.30%)

09/12/16
09/12/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pandora (P) upgraded to Buy from Neutral at SunTrust with analyst Robert Peck saying he thinks that a new interactive offering by the company could raise its contribution profit by 4%-9% and that the Street's 2017 estimates for the company "seem conservative." The analyst added that he thinks it's "very possible" that Pandora will be acquired. 2. AstraZeneca (AZN) upgraded to Buy from Hold at Jefferies with analyst Jeffrey Holford saying the company's MYSTIC oncology study could drive 39% share upside if successful. 3. Apache (APA) and upgraded to Overweight from Neutral at Atlantic Equities and to Peer Perform from Underperform at Wolfe Research. 4. Philip Morris (PM) upgraded to Conviction Buy from Neutral at Goldman with analyst Judy Hong saying she is increasingly bullish on the prospects of Next Generation Products and expects them to contribute 5%-6% of earnings by 2020. 5. Wal-Mart (WMT) upgraded to Outperform from Market Perform at Cowen with analysts led by Oliver Chen saying price investments, integration of physical and digital, and the Jet acquisitions position the company to regain its dominance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/13/16
EXAN
09/13/16
DOWNGRADE
EXAN
Neutral
AstraZeneca downgraded to Neutral from Outperform at Exane BNP Paribas
09/23/16
PIPR
09/23/16
INITIATION
PIPR
Overweight
AstraZeneca initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started AstraZeneca with an Overweight rating and GBP 60 price target.
09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

11:55
09/21/17
09/21
11:55
09/21/17
11:55
General news
Treasury Action: month- and quarter-end are quickly sneaking up »

Treasury Action: month-…

ICFI

ICF International

$50.95

-0.25 (-0.49%)

11:54
09/21/17
09/21
11:54
09/21/17
11:54
Conference/Events
ICF International management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

CRZBY

Commerzbank

$13.02

0.28 (2.20%)

, BNPQY

BNP Paribas

$39.58

-0.14 (-0.35%)

11:53
09/21/17
09/21
11:53
09/21/17
11:53
Periodicals
German government is favoring Commerzbank-BNP Paribas merger, CNBC says »

The German government is…

CRZBY

Commerzbank

$13.02

0.28 (2.20%)

BNPQY

BNP Paribas

$39.58

-0.14 (-0.35%)

UNCFF

UniCredit

$21.15

-0.14 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRVL

Marvell

$18.03

-0.12 (-0.66%)

11:50
09/21/17
09/21
11:50
09/21/17
11:50
Options
Put buyers active in Marvell as shares tick higher »

Put buyers active in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Oct

TSLA

Tesla

$373.91

-1.19 (-0.32%)

11:48
09/21/17
09/21
11:48
09/21/17
11:48
Periodicals
Tesla to stop selling cheapest Model S this weekend, Business Insider says »

Tesla will stop offering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

FANG

Diamondback Energy

$97.32

3.04 (3.22%)

11:45
09/21/17
09/21
11:45
09/21/17
11:45
Hot Stocks
Diamondback Energy EVP Molnar sells 5,000 shares »

Diamondback Energy's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FINL

Finish Line

$9.43

-0.13 (-1.36%)

11:40
09/21/17
09/21
11:40
09/21/17
11:40
Options
Large spread in Finish Line ahead of earnings »

Large spread in Finish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

11:40
09/21/17
09/21
11:40
09/21/17
11:40
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

SQ

Square

$28.24

-0.23 (-0.81%)

, INTC

Intel

$37.07

-0.16 (-0.43%)

11:32
09/21/17
09/21
11:32
09/21/17
11:32
Hot Stocks
Square names Intel's Naveen Rao to board »

Square (SQ) announced…

SQ

Square

$28.24

-0.23 (-0.81%)

INTC

Intel

$37.07

-0.16 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 23

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 05

    Oct

  • 22

    Oct

WASH

Washington Trust

$53.05

0.15 (0.28%)

11:31
09/21/17
09/21
11:31
09/21/17
11:31
Hot Stocks
Washington Trust increases quarterly dividend by 1c »

The board of Washington…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNCFF

UniCredit

$21.15

-0.14 (-0.66%)

, CRZBY

Commerzbank

$13.02

0.28 (2.20%)

11:30
09/21/17
09/21
11:30
09/21/17
11:30
Periodicals
UniCredit expresses interest in Commerzbank merger, Reuters reports »

UniCredit recently…

UNCFF

UniCredit

$21.15

-0.14 (-0.66%)

CRZBY

Commerzbank

$13.02

0.28 (2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OIH

Oil Services Holders Trust

$24.86

-0.33 (-1.31%)

11:30
09/21/17
09/21
11:30
09/21/17
11:30
Options
Short-term call buyers drilling for profits in Market Vectors Oil Services Fund »

Short-term call buyers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICPT

Intercept

$98.12

1.92 (2.00%)

11:29
09/21/17
09/21
11:29
09/21/17
11:29
Hot Stocks
Intercept sinks after FDA safety communication cites 19 patient deaths »

The FDA, in its safety…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHOR

ShoreTel

11:25
09/21/17
09/21
11:25
09/21/17
11:25
Hot Stocks
Breaking Hot Stocks news story on ShoreTel »

Gardner Lewis reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFX

Equifax

$97.46

1.46 (1.52%)

11:25
09/21/17
09/21
11:25
09/21/17
11:25
Periodicals
Equifax CEO to testify to Senate panel on October 4, Bloomberg says »

The Senate Banking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

FSLR

First Solar

$48.85

-0.01 (-0.02%)

, SPWR

SunPower

$7.86

-0.51 (-6.09%)

11:24
09/21/17
09/21
11:24
09/21/17
11:24
Hot Stocks
Before the Move: Watch First Solar, others ahead of ITC decision »

With an ITC Section 201…

FSLR

First Solar

$48.85

-0.01 (-0.02%)

SPWR

SunPower

$7.86

-0.51 (-6.09%)

CSIQ

Canadian Solar

$16.02

-0.69 (-4.13%)

JKS

JinkoSolar

$26.13

-0.16 (-0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLNG

Golar LNG

$21.15

0.66 (3.22%)

11:20
09/21/17
09/21
11:20
09/21/17
11:20
Options
Golar LNG calls active as shares see relative strength »

Golar LNG calls active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

11:17
09/21/17
09/21
11:17
09/21/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
09/21/17
09/21
11:16
09/21/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COF

Capital One

$81.16

-0.64 (-0.78%)

11:15
09/21/17
09/21
11:15
09/21/17
11:15
Options
Capital One put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 07

    Nov

11:15
09/21/17
09/21
11:15
09/21/17
11:15
General news
Treasury announced an $88 B 3-pronged package of coupon auctions »

Treasury announced an $88…

PEG

PSEG

$46.31

1.08 (2.39%)

11:10
09/21/17
09/21
11:10
09/21/17
11:10
Conference/Events
PSEG management to meet with Evercore ISI »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

  • 05

    Nov

11:08
09/21/17
09/21
11:08
09/21/17
11:08
General news
7-Yr Note Announcement CUSIP Number data reported »

7-Yr Note Announcement…

11:08
09/21/17
09/21
11:08
09/21/17
11:08
General news
7-Yr Note Announcement Offering Amount data reported »

7-Yr Note Announcement…

11:08
09/21/17
09/21
11:08
09/21/17
11:08
General news
5-Yr Note Announcement CUSIP Number data reported »

5-Yr Note Announcement…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.